Identification of Disease Specific Pathways and Modifiers in Phospholamban R14del Cardiomyopathy

Background

A specific mutation in phospholamban (the PLN R14del mutation), has its origin in the northern parts of the Netherlands (Figure) and causes a severe lethal dilated and/or an arrhythmogenic cardiomyopathy. A large proportion of the population of Groningen (1:1000) carries this mutation. Until now, there is no specific treatment available for patients with PLN cardiomyopathy. Patients are treated like any other type of heart failure patients, although PLN cardiomyopathy has a different etiology from "usual" heart failure. Treatment is therefore insufficient; malignant ventricular arrhythmias and end-stage heart failure at a young age are very prevalent. To develop treatment options, the investigators aim to study the following knowledge gaps:

* Pathophysiology. The clinical phenotype of PLN R14del cardiomyopathy bears characteristics of both arrhythmogenic and dilated cardiomyopathy (ACM and DCM). Using an "omics" approach of plasma, cardiac and skeletal muscle of patients and controls, the investigators aim to reveal distinct pathways affected by the mutant PLN, unique to the PLN R14del cardiomyopathy. This will be related to clinical data and mutant PLN expression levels in both cardiac and skeletal muscle biopsies. Using this extensive profiling, the investigators aim to identify disease mechanisms and provide the context for future risk stratification and disease progression monitoring. * Penetrance. Subjects with a heterozygous PLN R14del mutation show a wide variety in phenotype. Within the same family, patients can present either with over heart failure in their 20's or completely asymptomatic until at least their 70's. So far, no modifiers have been identified. The investigators will study cardiomyocytes derived from induced pluripotent stem cells from patients who are severely affected versus family members who are unaffected but carry the mutation. * Treatment response. The investigators have identified potential treatments, and confirmed their efficacy in in vivo models of PLN cardiomyopathy. To establish their efficacy in a human setting, the investigators will generate 3D cardiac tissues of cardiomyocytes gathered from induced pluripotent stem cells of patients affected in varying degrees and subject these tissues to the treatment.

Methods:

For the above purposes, the investigators will collect and analyze the following data/materials:

* Serum and plasma of 90 PLN R14del carriers: 30 unaffected, 30 early affected and 30 end stage. * Skin biopsy of 20 PLN R14del carriers: 10 unaffected, 10 end stage. * Cardiac muscle biopsy (obtained during left ventricular assist device [LVAD]/ heart transplant [HTx] surgery) of 30 patients: 10 R14del, 10 arrhythmogenic cardiomyopathy, 10 dilating cardiomyopathy. * Skeletal muscle biopsy of 10 patients: 5 R14del, 5 non R14del family members

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Phospholamban R14del Cardiomyopathy Cardiomyopathies Cardiomyopathy, Familial Cardiovascular Diseases Heart Diseases Heart Failure

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Medical Center Groningen

Groningen, 9700 RB, Netherlands

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

A minimum age of 18.
Of adequate communication.
Informed consent is obtained.
Genetically confirmed r14del mutation in PLN, family member or other DCM/ACM

Exclusion criteria

Known allergy for local anaesthetics.
Other subgroup specific exclusion criteria.

Treatment and study plan

Primary outcomes

The level of proteins in circulating blood and cardiac- and skeletal muscle tissue

Time frame: At baseline visit

An in-dept analyses of an extensive set of proteins assessed using large scale proteomic techniques to assess differences in individual protein levels and the total proteome of the circulating blood, cardiac tissue and skeletal muscle tissue of patients clinically differentially affected by the PLN R14del mutant protein.
The level of metabolites in circulating blood and cardiac- and skeletal muscle tissue

Time frame: At baseline visit

An in-dept analyses of an extensive set of metabolites assessed using large scale metabolomic techniques to assess differences in individual metabolite levels and the total metabolome of the circulating blood, cardiac tissue and skeletal muscle tissue of patients clinically differentially affected by the PLN R14del mutant protein
The level of mRNA in circulating blood and cardiac- and skeletal muscle tissue

Time frame: At baseline visit

An in-dept analyses of an extensive set of mRNA transcripts assessed using large scale transcriptomic techniques to assess differences in individual mRNA levels and the total transcriptome of the circulating blood, cardiac tissue and skeletal muscle tissue of patients clinically differentially affected by the PLN R14del mutant protein
The level of DNA methylation in cardiac muscle tissue

Time frame: At baseline visit

An in-dept analyses of differences in individual DNA methylation levels and patterns of cardiac tissue of patients clinically differentially affected by the PLN R14del mutant protein

Sponsors and collaborators

Lead sponsor

University Medical Center Groningen

Other

Collaborators

AstraZeneca

Registry information

Acronym: DECIPHER-PLN

Important dates

Study start: 2020
Primary completion: 2023
Study completion: 2023
First posted: Jul 27, 2021
Registry last updated: Aug 25, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed